Cotinga Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COTQF research report →
About the company
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene.
- CEO
- Richard T. Ho
- IPO
- 2009
- HQ
- Toronto, ON, CA
Price Chart
- Market Cap
- $2.20K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 132.92%
- ROIC
- 122.61%
- Revenue
- $0 · 0.00%
- Net Income
- $-2,005,115 · 47.33%
- EPS
- $-0.09 · 61.96%
- Op Income
- $-2,004,757
- FCF YoY
- 58.47%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -9.29
- Avg Volume
- 3.97K
Get TickerSpark's AI analysis on COTQF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our COTQF coverage
Recent articles, reports, and earnings notes.
No research on COTQF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COTQF report →Similar companies
Peers in the same neighborhood.